Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LSTA | LISATA THERAPEUTICS, INC. | 2025-10-30 15:04:08 | 2.67 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LSTA | 0000320017 | LISATA THERAPEUTICS, INC. | US1280583022 | — | 222343568 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 110 ALLEN ROAD | BASKING RIDGE | NJ | 07920 | UNITED STATES | US | 908-229-2590 | 110 ALLEN ROAD, BASKING RIDGE, NJ, 07920 | 110 ALLEN ROAD, BASKING RIDGE, NJ, 07920 | Caladrius Biosciences, Inc. | Biopharmaceuticals | — | David J. Mazzo | — | http://lisata.com | 27,700,000 | 8,627,202 | 8,755,948 | Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. | 2025-10-30 17:19:35 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 27,700,000 | 2,600,000 | 10.3586 | 8,620,162 | 312,729 | 3.7644 |
| 2023 | 25,100,000 | -6,200,000 | -19.8083 | 8,307,433 | 309,091 | 3.8644 |
| 2022 | 31,300,000 | -63,700,000 | -67.0526 | 7,998,342 | -52,523,293 | -86.7843 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James Nisco | Chief Accounting Officer, Senior Vice President | 2024 | 341,938 | 122,500 | 34,804 | — | 8,250 | 516,166 |
| Kristen K. Buck | Chief Medical Officer, Executive Vice President | 2024 | 597,421 | 299,671 | 129,360 | — | 8,250 | 1,065,061 |
| David J. Mazzo | Chief Executive Officer, President | 2024 | 702,969 | 387,876 | 468,160 | — | 30,250 | 1,691,174 |
| David J. Mazzo | Chief Executive Officer, President | 2023 | 675,931 | 382,282 | 258,000 | — | 30,250 | 1,408,382 |
| Kristen K. Buck | Chief Medical Officer, Executive Vice President | 2023 | 574,443 | 293,548 | 75,000 | — | 8,250 | 969,817 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 26 |
| 2023 | 25 |
| 2022 | 500 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1,000,000 | 0 | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 11,334,000 | 12,734,000 | 13,067,000 |
| General And Administrative Expenses | 12,075,000 | 12,974,000 | 14,141,000 |
| Operating Expenses | 23,409,000 | 25,708,000 | 57,601,000 |
| Operating Income | -22,409,000 | -25,708,000 | -57,601,000 |
| Net Income | -19,985,000 | -20,840,000 | -54,225,000 |
| Earnings Per Share Basic | -2.4 | -2.58 | -10.47 |
| Earnings Per Share Diluted | -2.4 | -2.58 | -10.47 |
| Weighted Average Shares Outstanding Basic | 8,329,000 | 8,073,000 | 5,180,000 |
| Weighted Average Shares Outstanding Diluted | 8,329,000 | 8,073,000 | 5,180,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 16,209,000 | 22,593,000 | 32,154,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 900,000 | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 34,578,000 | 53,924,000 | 71,876,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 72,000 | 175,000 | 296,000 |
| Other Assets Non Current | 160,000 | 332,000 | 528,000 |
| Total Assets Non Current | 424,000 | 770,000 | 1,158,000 |
| Total Assets | 35,002,000 | 54,694,000 | 73,034,000 |
| Accounts Payable | 1,284,000 | 2,421,000 | 2,655,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 4,329,000 | 4,169,000 | 3,728,000 |
| Total Liabilities Current | 5,613,000 | 6,590,000 | 6,383,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 72,000 | 210,000 | 327,000 |
| Total Liabilities Non Current | 72,000 | 210,000 | 327,000 |
| Total Liabilities | 5,685,000 | 6,800,000 | 6,710,000 |
| Common Stock | 8,000 | 8,000 | 8,000 |
| Retained Earnings | -548,066,000 | -528,081,000 | -507,241,000 |
| Accumulated Other Comprehensive Income | -81,000 | -42,000 | -29,000 |
| Total Shareholders Equity | 29,571,000 | 48,148,000 | 66,578,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 174,000 | 189,000 | 69,000 |
| Share Based Compensation Expense | 1,653,000 | 1,947,000 | 2,367,000 |
| Other Non Cash Income Expense | 0 | — | — |
| Change In Accounts Receivable | 900,000 | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -170,000 | -274,000 | -237,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -19,356,000 | -20,032,000 | -21,170,000 |
| Purchases Of Marketable Securities | 55,688,000 | 98,479,000 | 89,687,000 |
| Sales Of Marketable Securities | 69,051,000 | 108,581,000 | 122,203,000 |
| Acquisition Of Property Plant And Equipment | — | 0 | 285,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 13,233,000 | 10,102,000 | 28,911,000 |
| Tax Withholding For Share Based Compensation | 274,000 | 91,000 | 267,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 68,000 | 321,000 | 43,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -206,000 | 385,000 | -224,000 |
| Change In Cash | -6,384,000 | -9,561,000 | 7,507,000 |
| Cash At End Of Period | 16,209,000 | 22,593,000 | 32,154,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -2.4 | -2.58 | -10.47 |
| Price To Earnings Ratio | -1.2417 | -1.0581 | -0.2416 |
| Earnings Growth Rate | -6.9767 | -75.3582 | 1,994 |
| Price Earnings To Growth Ratio | 0.178 | 0.014 | -0.0001 |
| Book Value Per Share | 3.5199 | 5.9326 | 12.8039 |
| Price To Book Ratio | 0.8466 | 0.4602 | 0.1976 |
| Ebitda | -19,811,000 | -20,651,000 | -54,156,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 71,000 | 68,000 | 303,000 |
| Free Cash Flow | -19,427,000 | -20,100,000 | -21,473,000 |
| Return On Equity | -0.6758 | -0.4328 | -0.8145 |
| One Year Beta | 0.6755 | 0.683 | 0.7156 |
| Three Year Beta | 0.7152 | 0.8596 | 0.5815 |
| Five Year Beta | 0.6009 | 0.5814 | 0.5352 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Mazzo David J | Director, President & CEO | 2025-01-10 | 3,106 | D | 264,690 |
| Buck Kristen K | EVP, R&D and CMO | 2025-01-10 | 456 | D | 79,794 |
| Nisco James | SVP, Fin/Treas, Chief Actg Off | 2025-01-10 | 416 | D | 23,491 |
| AZAB MOHAMMAD | Director | 2025-01-09 | 15,789 | A | 74,469 |
| Flowers Cynthia Louise | Director | 2025-01-09 | 15,789 | A | 64,990 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cerity Partners LLC | 2025-09-30 | 30,702 | 12,183 | 2.5201 |
| MORGAN STANLEY | 2025-06-30 | 649 | 224 | 2.8973 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 3,836 | 1,323 | 2.8995 |
| RAYMOND JAMES FINANCIAL INC | 2025-06-30 | 17 | 6 | 2.8333 |
| BANK OF AMERICA CORP /DE/ | 2025-06-30 | 30,210 | 10,421 | 2.899 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 9,230 | 21,413.6 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 4,379 | 10,159.28 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 2,010 | 4,663.2 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 37,488 | 86,972.16 | 0.0002 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. Targeted Value Portfolio - Institutional Class | DFFVX | 3,039 | 7,536.72 | 0.0001 |